e-learning
resources
Milan 2017
Sunday, 10.09.2017
Markers of COPD progression
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY
M. Espinoza Solano (SEVILLA, Spain)
Source:
International Congress 2017 – Markers of COPD progression
Session:
Markers of COPD progression
Session type:
Thematic Poster
Number:
1083
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Espinoza Solano (SEVILLA, Spain). Evolution in the prescription of the therapy combined with ICS-LABA in COPD: TRACE STUDY. 1083
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
One-year efficacy of aclidinium/formoterol fixed-dose combination in COPD patients: The AUGMENT COPD study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The IMPACT of triple
versus
dual single-inhaler therapy on exacerbations of COPD
Source: Breathe, 14 (4) 333; 10.1183/20734735.026418
Year: 2018
Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY
Source: International Congress 2017 – Update and new perspectives in Airway Diseases
Year: 2017
Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
Source: International Congress 2018 – COPD management
Year: 2018
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
Source: ERJ Open Res, 8 (1) 00333-2021; 10.1183/23120541.00333-2021
Year: 2022
CAPTAIN: Effects of triple therapy on FEV1 response in patients with inadequately controlled asthma on ICS/LABA
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Single inhaler triple therapy in patients with COPD: patient-reported dyspnoea and health status from the IMPACT Trial
Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet?
Year: 2018
CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020
Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study
Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS
Year: 2018
What to use INSTEAD of inhaled corticosteroids in COPD?
Source: Eur Respir J 2014; 44: 1391-1393
Year: 2014
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Consistent benefit across multiple exacerbation endpoints
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
LATE-BREAKING ABSTRACT: Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone combination (SFC) in patients with COPD: the LANTERN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept